AChE/BChE/MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE and MAO-B that crosses the blood-brain barrier and exhibits inhibitory effects on hAChE, hBChE and hMAO-B with IC50s of 7.31, 0.56 and 26.1 μM, respectively. 1 had a neuroprotective effect and was not significantly cytotoxic.

ACHE-IN-38 is a potent Acetylcholinesterase inhibitor that can be used for the synthesis of compounds with anti-inflammatory, anti-tumor, and antibacterial activities.

ACHE Inhibitor 12 inhibited acetylcholinesterase with an IC50 value of 0.38 µM.

AChE-IN-43 is a potent, selective AChE inhibitor with a K i of 0.41 μM, applicable in the study of neurological diseases [1].

Compound AChE-IN-42, also known as Compound 28, is an acetylcholinesterase (AChE) inhibitor with an inhibition constant (K i) of 0.44 μM [1].

AChE-IN-3 had inhibitory effect on AChE and stronger inhibitory effect on NO, with EC50 of 0.57 μM.

AChE-IN-44 (Compound Tap4), an AChE inhibitor, is convertible into its thiazole salt form known as Tat2 [1].

AChE-IN-41 (Compound 2), a Galantamine-Memantine hybrid, possesses cholinesterase inhibitory capabilities. This compound demonstrates enhanced plasma stability and similar microsomal stability in vitro but has a reduced half-life and accelerated clearance in vivo [1].

AChE-IN-27 is a small molecule used for high-throughput assays.

AChE-IN-45 (Compound 14) is an acetylcholinesterase (AChE) inhibitor exhibiting an IC50 value of 11.57±0.45 nM, and it demonstrates both antioxidant and neuroprotective activities [1].

AChE/BuChE-IN-4 is a multi-target AChE/BuChE inhibitor with oral activity and blood-brain barrier permeability, with IC50 values of 2.08 and 7.41 μM for AChE and BuChE, respectively.

AChE-IN-20 is a potent inhibitor of AChE (IC50: 397.32 nM, Ki: 335.76 nM). AChE-IN-20 inhibits hCA-I (IC50: 84.14 nM, Ki: 97,86 nM), hCA-II (IC50: 69.24 nM, Ki: 76.23 nM) and α GLY (IC50: 52.08 nM, Ki: 57.93 nM).

AChE/BChE-IN-14 (compound 13), a benzylisoquinoline alkaloid extracted from Fissistigma polyanthum roots, demonstrates inhibitory effects on both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), coupled with antioxidant properties. This compound is pertinent to Alzheimer’s disease research [1].

AChE-IN-35 (compound 5g) serves as an acetylcholinesterase inhibitor, exhibiting an inhibitory concentration 50 (IC50) value of 5.88 μM [1].

AChE/BuChE/MAO-B-IN-2 (compound 4b) is a potent inhibitor of AChE, BuChE, and hu MAO-B, with respective IC50 values of 5.3 μM, 12.4 μM, and 1.9±0.08 μM, indicating good in vitro blood-brain barrier (BBB) permeability. It is effective in reducing excessive AChE and BuChE levels associated with Alzheimer's disease (AD) and holds potential for use in anti-Alzheimer's research [1].

AChE/BChE-IN-9 (Compound 7a) is a potent orally active inhibitor of AChE and BChE, with IC50 values of 5.74 μM and 14.05 μM against hAChE and eqBChE, respectively. It also demonstrates effective antioxidant activity, with an IC50 value of 57.35 μM. Additionally, AChE/BChE-IN-9 exhibits the ability to chelate iron and modulate the aggregation of amyloid β 1-42. Notably, AChE-IN-16 has the ability to cross the blood-brain barrier [1].

AChE-IN-15 (Compound 3d) is a reversible inhibitor of human acetylcholinesterase (huAChE) and human butyrylcholinesterase (huBChE) with IC50 values of 6.8 μM and 16.1 μM for huAChE and huBChE, respectively, with significant antioxidant activity. Alzheimer's disease.

sEH/AChE-IN-3 (15) serves as a dual inhibitor targeting both soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), demonstrating potent activity and the ability to cross the blood-brain barrier (BBB). It exhibits IC50 values of 0.4 nM for human sEH (hsEH), 1.94 nM for human AChE (hAChE), 615 nM for human butyrylcholinesterase (hBChE), 4.3 nM for mouse sEH (msEH), and 2.61 nM for mouse AChE (mAChE), indicating its efficacy across these enzymes.

Dual AChE-MAO B-IN-5, an indanone derivative, serves as an effective dual inhibitor for AChE and MAO-B, displaying IC50 values of 0.0224 μM for AChE, 0.0412 μM for MAO-B, and 0.1116 μM for MAO-A. Additionally, it exhibits antioxidant properties and inhibits β-amyloid plaque aggregation, making it suitable for Alzheimer’s disease (AD) research.

AChE/MAO-IN-1 is a potent inhibitor of human acetylcholinesterase (AChE), monoamine oxidase A (MAO-A), and monoamine oxidase B (MAO-B), demonstrating inhibitory concentrations (IC50) of 0.0248 μM, 0.0409 μM, and 0.1108 μM against AChE, MAO-A, and MAO-B, respectively.

Dual AChE-MAO B-IN-1 (compound 15) is a safe, metabolically stable neuroprotective agent.Dual AChE-MAO B-IN-1 is a potent, orally active CNS-permeable inhibitor of human AChE (IC50=550 nM) and MAO-B (IC50=8.2 nM), and has low in vitro activity against AChE and MAO-B with IC50 values of 550 nM, 8.2 nM respectively.

Dual AChE-MAO B-IN-2 is a potent, dual inhibitor of AChE (IC50: 0.12 μM) and MAO B (IC50: 0.01 μM).Dual AChE-MAO B-IN-2 has potential for Alzheimer's disease studies.

AChE/BChE-IN-1 is a potent dual inhibitor of acetylcholinesterase and butyrylcholinesterase with blood-brain barrier permeability, exhibiting an IC50 value of 1.06 and 7.3 nM for hAChE and hBChE, respectively, and showing antioxidant effects. AChE/BChE-IN-1 can be used in Alzheimer's disease research.

AChE-IN-6 is an optimal multifunctional ligand that significantly inhibits AChE activity with IC50 values of 0.20 μM and 37.02 nM for EeAChE and HuAChE, respectively, and has anti-Aβ activity (IC50= 1.92 μM for self-induced Aβ1-42 aggregation, IC50= 1.80 μM for disaggregation of Aβ1-42 pro AChE-IN-6 has shown research potential in Alzheimer's disease.

AChE-IN-22 (compound 10q) is a selective inhibitor of acetylcholinesterase (AChE) that acts on both AChE (IC50: 0.88 μM) and BuChE (IC50: 10 μM). AChE-IN-22 binds to both the CAS (catalytic active site) and PAS (peripheral anionic site) sites of AChE and can be used to study Alzheimer's disease.

AChE/BChE/BACE-1-IN-2 (Compound 4o) exhibits remarkable antioxidant potential and considerable binding capability towards PAS-AChE. AChE/BChE/BACE-1-IN-2 is an orally active AChE, BACE-1 and BChE inhibitor with IC 50 values of 0.069, 0.097 and 0.127 μM against hAChE, hBACE-1 and hBChE, respectively. AChE/BChE/BACE-1-IN-2 shows potential disassembly of Aβ aggregates and neuroprotective activity against Aβ-induced stress with excellent brain permeation [1].

AChE/BChE-IN-2 (Compound 13b) is a potent inhibitor of AChE/BChE with IC50 values of 0.96 ± 0.14 μM and 1.23 ± 0.23 μM for AChE and BChE, respectively.

AChE/BChE-IN-15 (Compound 6d) serves as an inhibitor for both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), presenting inhibition constants (IC50) of 20 nM for AChE and 220 nM for BChE. It interacts with the catalytic anionic site (CAS) and the peripheral anionic site (PAS) within the enzymes' active sites. AChE/BChE-IN-15 is applicable in Alzheimer’s disease research [1].

AChE-IN-29, a 3-OH pyrrolidine derivative, acts as a cholinesterase (ChE) inhibitor with potent activity against human acetylcholinesterase (hAChE), electric eel acetylcholinesterase (eeAChE), and equine butyrylcholinesterase (eqBChE), exhibiting IC50 values of 0.25 μM, 0.23 μM, and 0.72 μM, respectively. It is utilized in Alzheimer's disease research [1].

AChE-IN-40 (Compound 5C), with an inhibitory concentration 50 (IC50) of 120 nM, is an acetylcholinesterase (AChE) inhibitor suitable for Alzheimer's disease research [1].

AChE/BChE-IN-3 (BMC-1) hydrochloride is an AChE and BChE dual inhibitor. The IC50 values of AChE/BChE-IN-3 against equine serum BChE (eqBChE) and electric eel AChE (elAChE) is 0.383 μM and 6.08 μM, respectively [1].

AChE-IN-8 (Compound 19) is a highly potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 1.95 μM. This compound shows promise for further investigation in the research of Alzheimer's disease [1].

sEH/AChE-IN-4 -15 is a potent, blood-brain barrier-penetrating dual inhibitor targeting soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). It demonstrates notable inhibition efficacy, with IC50 values of 3.1 nM (hsEH), 1660 nM (hAChE), 179 nM (hBChE, human butyrylcholinesterase), 14.5 nM (msEH), and 102 nM (mAChE), indicating its significant inhibitory action across both targeted enzymes in human and mouse models.

AChE/BChE/MAO-B-IN-3, an indan-1-one derivative, serves as a potent inhibitor of human monoamine oxidase B (MAO-B) with an IC50 of 0.0359 μM, demonstrating significant inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 0.0473 μM and 0.0782 μM, respectively. Exhibiting notable antioxidant activity, AChE/BChE/MAO-B-IN-3 holds considerable promise for Alzheimer's disease (AD) research.

AChE/BChE/MAO-B-IN-4, an indan-1-one derivative, serves as a potent inhibitor for both monoamine oxidase B (MAO-B) and acetylcholinesterase/butyrylcholinesterase (AChE/BChE) enzymes. It exhibits a strong inhibitory effect on human MAO-B with an IC50 of 0.0393 μM, and demonstrates significant potency against human AChE and BChE enzymes with IC50 values of 0.0458 μM and 0.075 μM, respectively. Additionally, this compound displays notable antioxidant properties and the ability to prevent β-amyloid plaque aggregation, marking its potential utility in Alzheimer's disease (AD) research.

sEH/AChE-IN-2 and acetylcholinesterase ( AChE ). sEH/AChE-IN-2 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-2 has the potential for the research of Alzheimer's disease (AD) .

AChE/hCA I/II-IN-1 (Compound 6) is a potent AChE/Hca inhibitor with IC50 values of 22.21, 60.79 and 66.64 nM for AChE, Hca Ⅰ and Hca Ⅱ. AChE/hCA I/II-IN-1 can be used in glaucoma, Alzheimer's disease, and diabetes rsearch[1].

AChE-IN-26 (compound 4a) is an AChE (acetylcholinesterase) inhibitor (IC50: 0.42 μM).

AChE/BChE-IN-8 (Compound 5a) is an uncompetitive AChE and mixed BChE inhibitor. AChE/BChE-IN-8 shows Ki of 0.788 μM and 2.364 μM against Electrophorus electricus AChE (EeAChE) and equine BChE (eqBChE), respectively. AChE/BChE-IN-8 has blood-brain barrier permeability and low cytotoxicity.

AChE-IN-25 is a selective, potent, non-competitive inhibitor of acetylcholinesterase (AChE) with an IC50 value of 2.95 μM. AChE-IN-25 can be used to study Alzheimer's disease.

sEH/AChE-IN-1 (Compound 12a) is a dual inhibitor of soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-1 has a cumulative effect against neuroinflammation and memory impairment. sEH/AChE-IN-1 has shown research potential in Alzheimer's disease (AD).

AChE/BChE-IN-5 (BMC-16) is an AChE and BChE dual inhibitor that can cross the BBB. The IC 50 values of AChE/BChE-IN-5 for human AChE (hAChE) and human BChE (hBChE) are 266 nM and 10.6 nM , respectively [1].

AChE-IN-11 (compound 5C) can be used in the Alzheimer's disease research with neuroprotective effects and good antioxidant activity (ORAC = 2.5 eq). AChE-IN-11 is a good multifunctional agent with IC 50 values of 7.9 μM, 9.9 μM, and 8.3 μM against AChE, MAO-B, and BACE1. AChE-IN-11 has a mixed-type AChE inhibition that can bind to the CAS and PAS of AChE. AChE-IN-11 is also a selective metal ions chelator [1].

AChE-IN-34 (compound 5l) is a potent, selective AChE inhibitor exhibiting an IC50 of 3.98 µM and negligible BChE inhibition. It demonstrates mixed-mode inhibition of AChE with a Ki of 0.044 µM using acetylthiocholine substrate concentrations ranging from 0.1-1 mM [1].

AChE-IN-46 (compound 4), a β-cyclocostunolide, functions as an acetylcholinesterase (AChE) inhibitor [1].

AChE-IN-14 is a potent cholinesterase inhibitor, acting on electric eel acetylcholinesterase (eeAChE) (IC50: 0.46 μM), human recombinant acetylcholinesterase (hAChE) (IC50: 0.48 μM) and equine serum butyrylcholinesterase (eqBuChE) (IC50: 0.44 μM). AChE-IN-14 has a high affinity for the human H3 receptor (H3R) (Ki: 159.8 nM) and can be used to study Alzheimer's disease.

AChE/BChE-IN-11 (compound 1), a natural product derived from artichoke leaves, is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 70 μM for AChE and 71 μM for BChE, respectively. This compound is utilized in the research of Alzheimer’s disease (AD) [1].

AChE/BChE-IN-10 is a potent dual inhibitor of AChE and BChE with IC50 values of 0.176, and 0.47 μM, respectively. AChE/BChE-IN-10 exhibits good blood brain barrier permeability. AChE/BChE-IN-10 can inhibit Aβ-aggregation.

AChE/BuChE-IN-2 (Compound 5f) can cross the BBB that is an orally active inhibitor of AChE and BuChE with IC 50 values of 0.72 μM and 0.16 μM, respectively. AChE/BuChE-IN-2 shows potent inhibition of self-induced β-amyloid (Aβ) aggregation with an IC 50 of 62.52 μM and a non-competitive inhibition with AChE [1].

AChE/GSK-3β-IN-1 is a potent dual AChE/GSK-3β inhibitor that crosses the blood-brain barrier and acts on hAChE (IC50: 1.2 nM), hBChE (IC50: 149.8 nM) and hGSK-3β (IC50: 22.4 nM). AChE/GSK-3β-IN-1 is able to occupy the ATP binding site of DYRK1A. aChE/GSK-3β-IN-1 exhibits high kinase selectivity for the CMGC kinase family. aChE/GSK-3β-IN-1 inhibits ROS expression and reduces oxidative stress. aChE/GSK-3β-IN-1 can be used to study Alzheimer's disease.